Seeing the market potential for a next
Devices based on volumetric absorptive microsampling (VAMS) are thoroughly tested by five leading pharmaceutical organizations validating that they collect fixed volumes of blood, in a simple manner, while eliminating the volumetric hematocrit bias associated with DBS cards.
Due to the overwhelming success of the 10 µL Mitra device, a new company - Neoteryx - is spun off from Phenomenex to focus solely on developing, manufacturing, and selling novel microsampling devices based on VAMS technology.
VAMS technology, branded as the Mitra device, sees its commercial release in the 10 µL Clamshell format as a research use only device.
With the release of the 96-Rack Format, Neoteryx enters the realm of dried blood specimen automation. Now, labs can process hundreds or thousands of samples per day with standard liquid handling robotics.
As a CE-IVD registered device, Neoteryx is prepared to introduce the in vitro diagnostic European market to next generation dried blood collection and transportation.
The introduction of the ergonomic Cartridge format positions Mitra devices as a go-to solution for sampling outside the clinic by user themselves.
This award is a testament to the tenacity and diligence of the Research & Development team that helped make VAMS a reality and one of the most technologically significant innovations of 2015.
The Mitra microsampler is listed as an FDA Class 1 exempt medical device (D254936).
Responding to customer demand for a higher-volume specimen, Neoteryx releases 20 µL Mitra microsamplers to join the 10 µL devices launched in 2014.
Exagen Diagnostics changes the lanscape of rheumatology by launching a non‐invasive blood collection method that helps physicians and their patients monitor exposure levels to potentially toxic drugs from a single drop of blood.
Charles River Labs introduces its HemaTip™ product, based on VAMS technology, to transform the world of Serology Testing.
In a spirit of transparency, Neoteryx releases a beta version of the Cost Calculator For Clinical Trials. Now it is easy to see how VAMS technology implementation may reduce clinical trial costs.
To keep pace with demand, Neoteryx expands its operations and facilities, opening a third building on its campus in Torrance, California.
New research from the Mayo Clinic, presented at MSACL 2018 in Palm Springs (Califonia), indicates that it's Therapeutic Drug Monitoring patients strongly prefer this new sampling solution over older methods.
In a whirlwind of industry acclaim, more and more scientists and researchers are publishing about VAMS technology and their potential cost-saving and life-changing applications for it.
With the release of the 30 µL tips, users of Mitra devices now have more blood to facilitate their detection of analytes with low blood concentrations and to multiplex analyses from one sampler tip.